Skip to main content
INTERIM ANALYSIS OF PHASE 2 RESULTS FOR CEMIPLIMAB IN PATIENTS WITH METASTATIC BASAL CELL CARCINOMA (MBCC) WHO PROGRESSED ON OR ARE INTOLERANT TO HEDGEHOG INHIBITORS (HHIS) Lewis, K., Peris, K., Sekulic, A., Stratigos, A., Dunn, L., Eroglu, Z., Chang, A., Migden, M., Li, S., Mohan, K., Coates, E., Okoye, E., Baurain, J., Bechter, O., Hauschild, A., Butler, M., Hernandez-Aya, L., Licitra, L., Neves, R., Ruiz, E., Seebach, F., Weinreich, D., Yancopoulos, G., Lowy, I., Bowler, T., Fury, M. BMJ PUBLISHING GROUP. 2020: A260–A261

View details for DOI 10.1136/jitc-2020-SITC2020.0428

View details for Web of Science ID 000616665300416